Estimates overall survival, PSA progression-free survival, and probability of PSA response after ¹⁷⁷Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer.
INSTRUCTIONS
Enter the baseline clinical and PSMA PET/CT variables shown in the tool.
The calculator returns predicted overall survival, PSA progression-free survival, and PSA response outputs derived from the published LuPSMA nomograms.
